| Michelle Lynn Schwanke, MA, CCC-SLP/L | |
|
1035 Se 3rd St, Newton, KS 67114-3904 | |
| (316) 283-6600 | |
| Not Available |
| Full Name | Michelle Lynn Schwanke |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1035 Se 3rd St, Newton, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841983921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michelle Lynn Schwanke, MA, CCC-SLP/L 4504 E Norwood Ln, Wichita, KS 67220-2303 Ph: (316) 204-1573 | Michelle Lynn Schwanke, MA, CCC-SLP/L 1035 Se 3rd St, Newton, KS 67114-3904 Ph: (316) 283-6600 |
News Archive
The rarity of spinal muscular atrophy (SMA) means that promising new treatments may be tested in only a limited spectrum of patients before approval. Investigators evaluated a newly approved drug, onasemnogene abeparvovec, in a broader spectrum of patients in order to obtain expanded data on its side effects profile.
DURECT Corporation announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR™ (SABER™-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial, referred to as BESST (Bupivacaine Effectiveness and Safety in SABER Trial), is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in patients undergoing general surgical procedures.
Creighton University School of Nursing has received a $207,000, two-year grant from the National Institutes of Health to address the growing problem of type 2 diabetes mellitus in adult American Indians.
Scientists have identified a new mutation in the gene that causes the inherited disease known as Alpha-1 Antitrypsin Deficiency (Alpha-1), which affects roughly one in 2,500 people of European descent.
Strong relationships with physicians, particularly those that are long standing, are likely to increase patients' openness to talk about health care costs when decisions are being made about their treatment options.
› Verified 1 days ago
Mrs. Keri Annette Mick, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: Newton Presbyterian Manor, 7th Street, Newton, KS 67114 Phone: 316-284-5981 | |
Mrs. Jodi Kathleen Wondra, MA, CCC/SLP-L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2215 S Duncan St, Newton, KS 67114 Phone: 316-283-4934 Fax: 316-804-6265 | |
Mrs. Stephanie Anne Pham, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7310 Ne 36th St, Newton, KS 67114 Phone: 316-727-6973 | |
Mrs. Morgan L Simmons, MS CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 600 Medical Center Dr, Newton, KS 67114 Phone: 316-283-2700 | |
Justine Unruh, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 510 E Wheatridge Dr, Newton, KS 67114 Phone: 316-836-4700 Fax: 316-836-4750 | |
Mrs. Lauren Elizabeth Campbell, M.A SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 600 Medical Center Dr, Newton, KS 67114 Phone: 316-283-2700 Fax: 316-836-4705 | |
Jamie Lee Karst, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 600 Medical Center Dr, Newton, KS 67114 Phone: 316-283-2700 |